“…This newer adipokine appears to be one of the most probable candidates involved in the pathophysiology of GDM, similarly to well-known and verified markers of diabetes and obesity, such as adiponectin, leptin, and tumour necrosis factor α (TNFα) [11,12,13]. Furthermore, the roles of FABP4 in the development of adiposity, insulin resistance, T2DM, atherosclerosis, hypertension, coronary artery and cerebrovascular diseases, as well as metabolic syndrome, are of great concern [14,15,16,17,18].…”